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Abstract
There is scant literature regarding the psychological
effects of intravenous immunoglobulin (IVIG) treatment
experience on quality of life (QOL) for neurological
autoimmune disease patients diagnosed with multiple
sclerosis, multifocal motor neuropathy, myasthenia
gravis, and chronic inflammatory demyelinating
polyneuropathy. IVIG treatment experience predicted
QOL in 1 Neuro-QOL subscale; illness intrusiveness
mediated 9 of the Neuro-QOL subscales using biascorrected bootstrapping for statistical significance; and
personal control did not mediate the relationship
between illness intrusiveness and QOL.

Problem
IVIG (a purified blood product providing healthy
antibodies) is the treatment of choice for the four
neurological autoimmune diseases examined (MS,
MMN, MG and CIDP).

The high cost of the therapy, complicated
schedules, and long hours of infusions may cause
disruptions to the lives of the neurological autoimmune
patients who receive it affecting illness
intrusiveness.

Relevant Literature
The illness intrusiveness framework posits that
disease and/or treatment factors affect illness
intrusiveness which directly affects QOL. Illness
intrusiveness is a mediating variable between the
disease treatment and QOL (Devins, 2010).

QOL is compromised and perception of control
decreased when the disease treatment interferes with
goals, interests, and enjoyable activities (Devins,
2010; Poochikian-Sarkissian et al., 2008).
Treatment factors have been shown to be affiliated
with increased illness intrusiveness (Bettazzoni et al.,
2008; Devins et al., 1990; Poochikian-Sarkissian et.
al., 2008).

RQ1: Is the IVIG treatment experience (as measured
by the Visual Analogue Scale) a significant predictor
of QOL (as measured by 10 Neuro-QOL scales) in
patients with autoimmune disorders who receive IVIG
treatment?

Illness intrusiveness has been shown to be a
mediator in other chronic diseases (Dancey, HuttonYoung, Moye, & Devins, 2002; Shawaryn et al., 2002).
Control was examined as a mediator between illness
intrusiveness and QOL which might shed light on why
some patients may be more affected than others by
the treatment.

RQ3: Does personal control mediate the relationship
between illness intrusiveness and QOL (as measured
by 10 Neuro-QOL scales) among individuals with
autoimmune disease who receive IVIG treatment?

The purpose of this quantitative, survey research study
was to examine the relationship between the IVIG
treatment experience (predictor variable) and QOL
(outcome variable) in neurological autoimmune
patients. Illness intrusiveness and personal control
were studied as potential mediators.

Results

Mediation analysis was used to estimate the
coefficients of the model, analyze, and interpret the
direct, indirect, and total effects (paths a, b, ab, c, c′).
Bias-corrected bootstrap confidence intervals were
estimated as well as effect sizes (Hayes, 2013).
Noted in Table 1 are the results of mediation
analyses of the 10 Neuro-QOL variables:
satisfaction with social roles & activities, depression,
fatigue, positive attitude & well-being, sleep, stigma,
cognition, emotional & behavioral dyscontrol, lower
extremity function, and upper extremity function.

Table 1

Research Questions

RQ2: Does illness intrusiveness mediate the
relationship between IVIG treatment experience and
QOL (as measured by 10 Neuro-QOL scales) among
individuals with autoimmune disease who received
IVIG treatment?

Purpose

Data Analysis

Procedures
The sample was convenience/nonrandom, and
included 25 male and 54 female patients. Diagnoses
were 30 MS, 25 CIDP, 13 MG, and 11 MMN.

Surveys included the IVIG experience visual analog
scale, the IIRS scale, MHLC-Form C, and 10 NeuroQOL subscales.

QOL
Outcomes

P - Value

Variance Mediation/
Explained Effect Size

SSRA

p ˂ .001

46%

Depression

p ˂ .001

33%

Fatigue

p ˂ .001

39%

PAWB

p ˂ .001

27%

Sleep

p ˂ .001

36%

Stigma

p ˂ .001

25%

Cognition

p = .001

16%

EBD

p < .001

20%

LEF

P = .01

11%

UEF

p = .353

3%

Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Medium
Yes/
Small
None

Dissertation Chair: Silvia Bigatti; Second Committee Member: Rachel Piferi; University Research Reviewer: Susan Marcus

RQ1: IVIG treatment experience significantly
correlated with QOL PAWB.
RQ2: Illness intrusiveness mediated the relationship
between IVIG treatment experience and 9 of the
Neuro-QOL subscales.
RQ3: Personal control did not mediate illness
intrusiveness and QOL.

Limitations
All 79 patients came from the same infusion center so
generalizing to similar centers may be possible but a
national population generalization may not be
possible.
Patients could not be randomly selected, but
volunteered. Question #13 of the IIRS was
inadvertently omitted from the survey given to
participants.

Conclusions
Findings show that how patients interpret or perceive
the level of intrusiveness of IVIG influences their QOL.
The indirect effects showed the more positive the IVIG
experience the less the patient experienced illness
intrusiveness and vice versa in 9 areas of QOL. Less
illness intrusiveness indicated increased QOL.
The results may be helpful in identifying areas where
IVIG patients deem the treatment experience
interferes with their lifestyle.

Social Change Implications
This study expands research for immunoglobulin (Ig)
therapy and serves to advance the practice of nursing
and education, management, and clinical practice for
patients receiving this treatment.
Results from the study may provide insight for
interventions to assist patients in adjusting to
treatment.

